| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.
|
JAMA
|
2006
|
11.71
|
|
2
|
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators.
|
PLoS Med
|
2006
|
8.57
|
|
3
|
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
|
N Engl J Med
|
2014
|
4.90
|
|
4
|
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
|
Lancet Infect Dis
|
2013
|
3.17
|
|
5
|
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
|
N Engl J Med
|
2015
|
3.13
|
|
6
|
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.
|
Liver Int
|
2011
|
2.77
|
|
7
|
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
|
N Engl J Med
|
2015
|
2.17
|
|
8
|
Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis.
|
J Infect Dis
|
2012
|
2.00
|
|
9
|
African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology.
|
Nutr J
|
2005
|
1.99
|
|
10
|
Barriers to participating in an HIV vaccine trial: a systematic review.
|
AIDS
|
2004
|
1.97
|
|
11
|
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.
|
Can J Gastroenterol Hepatol
|
2015
|
1.86
|
|
12
|
Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus.
|
Clin Infect Dis
|
2012
|
1.71
|
|
13
|
Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda.
|
AIDS
|
2011
|
1.55
|
|
14
|
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
|
Nat Rev Gastroenterol Hepatol
|
2011
|
1.46
|
|
15
|
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
|
Liver Int
|
2014
|
1.42
|
|
16
|
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.
|
Hepatology
|
2013
|
1.38
|
|
17
|
HIV/AIDS in African militaries: an ecological analysis.
|
Med Confl Surviv
|
2008
|
1.34
|
|
18
|
Users' guides to the medical literature: how to use an article about mortality in a humanitarian emergency.
|
Confl Health
|
2008
|
1.28
|
|
19
|
Cohort profile: the Canadian Observational Cohort collaboration.
|
Int J Epidemiol
|
2010
|
1.27
|
|
20
|
Traditional African medicine in the treatment of HIV.
|
Lancet Infect Dis
|
2005
|
1.23
|
|
21
|
Adherence to antiretroviral therapy among a conflict-affected population in Northeastern Uganda: a qualitative study.
|
AIDS
|
2008
|
1.22
|
|
22
|
Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study.
|
Int J Epidemiol
|
2009
|
1.17
|
|
23
|
Barriers to participation in HIV drug trials: a systematic review.
|
Lancet Infect Dis
|
2006
|
1.17
|
|
24
|
Cohort profile: the Ontario HIV Treatment Network Cohort Study (OCS).
|
Int J Epidemiol
|
2012
|
1.14
|
|
25
|
Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy.
|
PLoS One
|
2013
|
1.08
|
|
26
|
A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression.
|
J Acquir Immune Defic Syndr
|
2010
|
1.05
|
|
27
|
The management of chronic viral hepatitis: a Canadian consensus conference 2004.
|
Can J Gastroenterol
|
2004
|
1.04
|
|
28
|
Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study.
|
BMC Med Res Methodol
|
2013
|
1.01
|
|
29
|
Pediatric HIV therapy in armed conflict.
|
AIDS
|
2008
|
0.99
|
|
30
|
Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013).
|
AIDS
|
2014
|
0.98
|
|
31
|
Once daily dosing improves adherence to antiretroviral therapy.
|
AIDS Behav
|
2011
|
0.97
|
|
32
|
Evaluation of health care needs and patient satisfaction among hepatitis C patients treated at a hospital-based, viral hepatitis clinic.
|
Can J Public Health
|
2004
|
0.96
|
|
33
|
Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation.
|
BMC Public Health
|
2014
|
0.96
|
|
34
|
The management of chronic viral hepatitis: A Canadian consensus conference 2004.
|
Can J Infect Dis Med Microbiol
|
2004
|
0.95
|
|
35
|
Orphanhood predicts delayed access to care in Ugandan children.
|
Pediatr Infect Dis J
|
2009
|
0.94
|
|
36
|
Ensuring sustainable antiretroviral provision during economic crises.
|
AIDS
|
2010
|
0.94
|
|
37
|
Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada).
|
Can J Gastroenterol
|
2011
|
0.94
|
|
38
|
Simple, effective interventions are key to improving adherence in marginalized populations.
|
Clin Infect Dis
|
2007
|
0.93
|
|
39
|
Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis.
|
Ann Clin Microbiol Antimicrob
|
2009
|
0.93
|
|
40
|
Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy.
|
Expert Opin Biol Ther
|
2007
|
0.93
|
|
41
|
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
|
Gastroenterology
|
2013
|
0.92
|
|
42
|
Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals.
|
Antivir Ther
|
2014
|
0.92
|
|
43
|
Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.
|
BMC Infect Dis
|
2010
|
0.91
|
|
44
|
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
|
Vaccine
|
2012
|
0.90
|
|
45
|
Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison.
|
Hum Vaccin Immunother
|
2013
|
0.89
|
|
46
|
A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases.
|
Drugs R D
|
2008
|
0.88
|
|
47
|
Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis.
|
Clin Infect Dis
|
2013
|
0.86
|
|
48
|
Evaluation of immigration status, race and language barriers on chronic hepatitis C virus infection management and treatment outcomes.
|
Eur J Gastroenterol Hepatol
|
2009
|
0.85
|
|
49
|
Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
|
J Acquir Immune Defic Syndr
|
2011
|
0.85
|
|
50
|
Clinical significance of hepatitis B core antibody positivity in HCV-infected and HCV/HIV coinfected individuals.
|
Clin Infect Dis
|
2004
|
0.85
|
|
51
|
Implementation and Operational Research: Engagement in HIV Care Among Persons Enrolled in a Clinical HIV Cohort in Ontario, Canada, 2001-2011.
|
J Acquir Immune Defic Syndr
|
2015
|
0.84
|
|
52
|
Liver toxicity resulting from syphilis and Jarish-Herxheimer reaction in cases of coinfection with HIV and hepatitis C virus.
|
Clin Infect Dis
|
2005
|
0.83
|
|
53
|
Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals.
|
Antivir Ther
|
2012
|
0.83
|
|
54
|
Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history.
|
AIDS
|
2014
|
0.83
|
|
55
|
Long-term health care interruptions among HIV-positive patients in Uganda.
|
J Acquir Immune Defic Syndr
|
2013
|
0.83
|
|
56
|
Reassessing the role for lamivudine in chronic hepatitis B infection: a four-year cohort analysis.
|
Can J Gastroenterol
|
2012
|
0.83
|
|
57
|
The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era.
|
Can J Gastroenterol Hepatol
|
2014
|
0.82
|
|
58
|
Impact of hepatitis B and C co-infection on health-related quality of life in HIV positive individuals.
|
Qual Life Res
|
2012
|
0.81
|
|
59
|
The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus.
|
PLoS One
|
2011
|
0.81
|
|
60
|
Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients.
|
AIDS
|
2012
|
0.81
|
|
61
|
Depression and cigarette smoking independently relate to reduced health-related quality of life among Canadians living with hepatitis C.
|
Can J Gastroenterol
|
2006
|
0.81
|
|
62
|
Randomized trials stopped early for harm in HIV/AIDS: a systematic survey.
|
HIV Clin Trials
|
2006
|
0.80
|
|
63
|
CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy.
|
Contemp Clin Trials
|
2008
|
0.80
|
|
64
|
Gender disparities in HIV risk behavior and access to health care in St. Petersburg, Russia.
|
AIDS Patient Care STDS
|
2013
|
0.80
|
|
65
|
Factors associated with late initiation of highly active antiretroviral therapy among young HIV-positive men and women aged 18 to 29 years in Canada.
|
J Int Assoc Provid AIDS Care
|
2013
|
0.79
|
|
66
|
Clinical impact of altered T-cell homeostasis in treated HIV patients enrolled in a large observational cohort.
|
AIDS
|
2013
|
0.79
|
|
67
|
Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
|
Transplantation
|
2016
|
0.79
|
|
68
|
Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant.
|
Leuk Lymphoma
|
2013
|
0.79
|
|
69
|
Impact of the Data Collection on Adverse Events of Anti-HIV Drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada.
|
J Int Assoc Provid AIDS Care
|
2013
|
0.78
|
|
70
|
HIV knowledge among Canadian-born and sub-Saharan African-born patients living with HIV.
|
J Immigr Minor Health
|
2012
|
0.78
|
|
71
|
High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.
|
J Clin Immunol
|
2014
|
0.78
|
|
72
|
The influence of race and language on chronic hepatitis C virus infection management.
|
Eur J Gastroenterol Hepatol
|
2009
|
0.78
|
|
73
|
Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes.
|
Can J Gastroenterol Hepatol
|
2014
|
0.77
|
|
74
|
Validation of the Episodic Disability Framework with adults living with HIV.
|
Disabil Rehabil
|
2013
|
0.77
|
|
75
|
Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation.
|
J Clin Pharmacol
|
2015
|
0.77
|
|
76
|
Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfected patients.
|
AIDS
|
2016
|
0.76
|
|
77
|
Time-dependent bias in hepatitis C classification.
|
Epidemiology
|
2015
|
0.76
|
|
78
|
Relationships between dimensions of disability experienced by adults living with HIV: a structural equation model analysis.
|
AIDS Behav
|
2014
|
0.76
|
|
79
|
Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study.
|
HIV Clin Trials
|
2015
|
0.76
|
|
80
|
Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.
|
Can J Gastroenterol Hepatol
|
2013
|
0.75
|
|
81
|
Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysis.
|
Can J Gastroenterol
|
2013
|
0.75
|
|
82
|
Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial.
|
Hum Vaccin Immunother
|
2013
|
0.75
|
|
83
|
Interferon-based hepatitis C antiviral treatment outcomes may be predicted by alanine aminotransferase levels.
|
Can J Gastroenterol Hepatol
|
2015
|
0.75
|
|
84
|
A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
85
|
Missed opportunities for hepatocellular carcinoma screening in an HIV/hepatitis C virus-coinfected cohort.
|
Clin Infect Dis
|
2013
|
0.75
|
|
86
|
Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada.
|
Can J Public Health
|
2017
|
0.75
|
|
87
|
The use of multistate models to examine associations of stress and adherence with transitions among HIV care states observed in a clinical HIV cohort.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
88
|
HIV-HCV Co-infection therapeutic outcomes have not improved over time.
|
HIV Clin Trials
|
2009
|
0.75
|
|
89
|
Gastrointestinal Symptom Distress is Associated With Worse Mental and Physical Health-Related Quality of Life.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|